Home・Listă Acțiuni・Vaxcyte Inc

Vaxcyte Inc

Închisă

SectorSănătate

57.9 -1.68

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

56.58

Maxim

59.63

Indicatori cheie
By Trading Economics
Venit	-74M -321M
EPS	-2.3
Angajați	507
EBITDA	-80M -315M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+94.14% upside

Dividende
By Acuity
Următoarele câștiguri	11 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-716M 7.7B
Deschiderea anterioară	59.58
Închiderea anterioară	57.9

Sentimentul știrilor

By Acuity

50%

151 / 340 Clasament în Healthcare

Vaxcyte Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 aug. 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 aug. 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 aug. 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 aug. 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 iul. 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 iul. 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 iul. 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 iul. 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 iul. 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 iul. 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 iul. 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Comparație

Modificare preț

Vaxcyte Inc Așteptări

Obiectiv de preț

By TipRanks

94.14% sus

Prognoză pe 12 luni

Medie 114.33 USD 94.14%

Maxim 163 USD

Minim 75 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVaxcyte Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Vaxcyte Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

151 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.